TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy

Biochemical and Biophysical Research Communications

Volumn 338, Issue 4, 2005, Pages 1745-1750

  Schoppet, Michael ^a   Ruppert, Volker ^a   Hofbauer, Lorenz C ^a   Henser, Stephanie ^a   Al Fakhri, Nadia ^a   Christ, Michael ^a,b   Pankuweit, Sabine ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Apoptosis; Dilated cardiomyopathy; Heart failure; Osteoprotegerin; TRAIL

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ANGIOCARDIOGRAPHY; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HEART MUSCLE BIOPSY; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; APOPTOSIS REGULATORY PROTEINS; BIOPSY; CARDIOMYOPATHY, DILATED; FETAL HEART; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYOCARDIUM; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 27844497509     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.10.136     Document Type: Article

References (34)

1. J. Schonberger, and C.E. Seidman Many roads lead to a broken heart: the genetics of dilated cardiomyopathy Am. J. Hum. Genet. 69 2001 249 260
2. W. Grimm, M. Christ, J. Bach, H.H. Muller, and B. Maisch Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study Circulation 108 2003 2883 2891
3. R. Mobini, H. Maschke, and F. Waagstein New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy Autoimmun. Rev. 3 2004 277 284
4. J. Narula, N. Haider, R. Virmani, T.G. DiSalvo, F.D. Kolodgie, R.J. Hajjar, U. Schmidt, M.J. Semigran, G.W. Dec, and B.A. Khaw Apoptosis in myocytes in end-stage heart failure N. Engl. J. Med. 335 1996 1182 1189
5. T. Arimura, T. Hayashi, H. Terada, S.Y. Lee, Q. Zhou, M. Takahashi, K. Ueda, T. Nouchi, S. Hohda, M. Shibutani, M. Hirose, J. Chen, J.E. Park, M. Yasunami, H. Hayashi, and A. Kimura A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C J. Biol. Chem. 279 2004 6746 6752
6. G. Olivetti, R. Abbi, F. Quaini, J. Kajstura, W. Cheng, J.A. Nitahara, E. Quaini, C. Di Loreto, C.A. Beltrami, S. Krajewski, J.C. Reed, and P. Anversa Apoptosis in the failing human heart N. Engl. J. Med. 336 1997 1131 1141
7. S.E. Hughes Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon? J. Pathol. 20 2003 181 186
8. S. Kostin, L. Pool, A. Elsasser, S. Hein, H.C. Drexler, E. Arnon, Y. Hayakawa, R. Zimmermann, E. Bauer, W.P. Klovekorn, and J. Schaper Myocytes die by multiple mechanisms in failing human hearts Circ. Res. 92 2003 715 724
9. J.P. Sheridan, S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C.L. Gray, K. Baker, W.I. Wood, A.D. Goddard, P. Godowski, and A. Ashkenazi Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 277 1997 818 821
10. M.R. Sprick, M.A. Weigand, E. Rieser, C.T. Rauch, P. Juo, J. Blenis, P.H. Krammer, and H. Walczak FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 Immunity 12 2000 599 609
11. S. Wang, and W.S. El-Deiry TRAIL and apoptosis induction by TNF-family death receptors Oncogene 22 2003 8628 8633
12. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. Appelbaum, C. Eichman, R. Di Prinzio, R.A. Dodds, I.E. James, M. Rosenberg, J.C. Lee, and P.R. Young Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J. Biol. Chem. 273 1998 14363 14367
13. M. Jo, T.H. Kim, D.W. Seol, J.E. Esplen, K. Dorko, T.R. Billiar, and S.C. Strom Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat. Med. 6 2000 564 567
14. W.L. Henry, J.M. Gardin, and J.H. Ware Echocardiographic measurements in normal subjects from infancy to old age Circulation 62 1980 1054 1061
15. S. Pankuweit, R. Moll, U. Baandrup, I. Portig, G. Hufnagel, and B. Maisch Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens Hum. Pathol. 34 2003 497 500
16. L.C. Hofbauer, S. Kluger, C.A. Kuhne, C.R. Dunstan, A. Burchert, M. Schoppet, A. Zielke, and A.E. Heufelder Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland J. Cell. Biochem. 86 2002 642 650
17. M.W. Pfaff A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res. 29 2001 2002 2007
18. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc. Natl. Acad. Sci. USA 95 1998 3597 3602
19. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, and W.S. Simonet Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev. 12 1998 1260 1268
20. P. Collin-Osdoby Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin Circulation 95 2004 1046 1057
21. T. Ueland, R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland, I.B. Squire, L. Gullestad, J. Bollerslev, K. Dickstein, and P. Aukrust Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction J. Am. Coll. Cardiol. 44 2004 1970 1976
22. L.B. Pritzker, M. Scatena, and C.M. Giachelli The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival Mol. Biol. Cell 15 2004 2834 2841
23. T. Miyashita, A. Kawakami, T. Nakashima, S. Yamasaki, M. Tamai, F. Tanaka, M. Kamachi, H. Ida, K. Migita, T. Origuchi, K. Nakao, and K. Eguchi Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovila cells Clin. Exp. Immunol. 137 2004 430 436
24. D.C. Spierings, E.G. de Vries, E. Vellenga, F.A. van den Heuvel, J.J. Koornstra, J. Wesseling, H. Hollema, and S. de Jong Tissue distribution of the death ligand TRAIL and its receptors J. Histochem. Cytochem. 52 2004 821 831
25. N. Latif, M.A. Khan, E. Birks, A. O'Farrell, J. Westbrook, M.J. Dunn, and M.H. Yacoub Upregulation of the Bcl-2 family of proteins in end stage heart failure J. Am. Coll. Cardiol. 35 2000 1769 1777
26. K. Nishigaki, S. Minatoguchi, M. Seishima, K. Asano, T. Noda, N. Yasuda, H. Sano, H. Kumada, M. Takemura, A. Noma, T. Tanaka, S. Watanabe, and H. Fujiwara Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure J. Am. Coll. Cardiol. 29 1997 1214 1220
27. T. Yamamura, H. Nakamura, T. Yamamoto, S. Umemoto, T. Fujii, N. Kobayashi, and M. Matsuzaki Fas expression and apoptosis correlate with cardiac dysfunction in patients with dilated cardiomyopathy Jpn. Circ. J. 63 1999 149 154
28. T. Ueland, A. Yndestad, E. Oie, G. Florholmen, B. Halvorsen, S.S. Froland, S. Simonsen, G. Christensen, L. Gullestad, and P. Aukrust Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure Circulation 111 2005 2461 2468
29. B. Felzen, M. Shilkrut, H. Less, I. Sarapov, G. Maor, R. Coleman, R.B. Robinson, G. Berke, and O. Binah Fas (CD95/Apo-1)-mediated damage to ventricular myocytes induced by cytotoxic T lymphocytes from perforin-deficient mice: a major role for inositol 1,4,5-trisphosphate Circ. Res. 82 1998 438 450
30. A. Yndestad, J.K. Damas, H.G. Eiken, T. Holm, T. Haug, S. Simonsen, S.S. Froland, L. Gullestad, and P. Aukrust Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure Cardiovasc. Res. 54 2002 175 182
31. W. Matsuyama, M. Yamamoto, I. Higashimoto, K. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, and K. Arimura TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus Blood 104 2004 184 191
32. D. Wencker, M. Chandra, K. Nguyen, W. Miao, S. Garantziotis, S.M. Factor, J. Shirani, R.C. Armstrong, and R.N. Kitsis A mechanistic role for cardiac myocyte apoptosis in heart failure J. Clin. Invest. 111 2003 1497 1504
33. Y. Hayakawa, M. Chandra, W. Miao, J. Shirani, J.H. Brown, G.W. Dorn, R.C. Armstrong, and R.N. Kitsis Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice Circulation 108 2003 3036 3041
34. R. Neviere, H. Fauvel, C. Chopin, P. Formstecher, and P. Marchetti Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis Am. J. Respir. Crit. Care Med. 163 2001 218 225